SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of HD Supply Holdings, Inc. Buyout

WILMINGTON, Del., Nov. 16, 2020 (GLOBE NEWSWIRE) — Rigrodsky & Long, P.A. announces that it is investigating HD Supply Holdings, Inc. (“HD Supply”) (NASDAQ GS: HDS) regarding possible breaches of fiduciary duties and other violations of law related to HD Supply’s agreement to be acquired by The Home Depot, Inc. (“Home Depot”) (NYSE: HD). Under the terms of the agreement, HP Supply’s shareholders will receive $56.00 in cash per share.

To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-hd-supply-holdings-inc.

You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or [email protected].

Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising.  Prior results do not guarantee a similar outcome.

CONTACT:         

Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242 (Toll Free)
(302) 295-5310
Fax: (302) 654-7530
[email protected]
https://rl-legal.com



Eclipse Senior Living Launches Empower Hour Webcast Aimed at Helping Family Caregivers Navigate Uncertain Times

The new series reinforces the senior living brand’s commitment to cultivating healthy, happy communities

LAKE OSWEGO, Ore., Nov. 16, 2020 (GLOBE NEWSWIRE) — Eclipse Senior Living, a national manager of distinctive Independent, Assisted Living and Memory Care communities across the United States, today announced the launch of Empower Hour, a new webcast series dedicated to supporting family caregivers as they navigate the uncertainties and challenges of life while caring for an aging loved one. The series premiere, “5+ Things to Know When Caring for an Aging Loved One During the Holidays,” will webcast on Wednesday, November 18 at 12 p.m. PT / 3 p.m. ET. A recording of the webcast will be available following the live event.

Empower Hour comes at a time when more people than ever are taking on the role of family caregiver. According to data from the National Alliance for Caregiving and AARP, roughly 34.2 million Americans had provided unpaid care to an adult age 50 or older in the last 12 months.1 And all of those hours of unpaid care add up — on average, caregivers spend 13 days per month on household tasks, 6 days per month assisting with personal tasks and 13 hours per month researching diseases and coordinating medical visits.2

“Holidays present unique challenges for family caregivers, and those challenges are amplified this year due to the ongoing COVID-19 pandemic,” said Sharon Roth Maguire, Eclipse Senior Living’s senior vice president of wellness, care and quality. “We’re thrilled to be kicking off Empower Hour with an impactful examination of one of the most challenging times of the year for caregivers.”

Participants who tune into the premiere Empower Hour webcast have the opportunity to
hear from Eclipse’s national experts on geriatric care and dementia, and learn more about important topics related to family caregiving, including:

  • The changing perceptions and expectations of family caregiving today
  • Understanding the dynamics of family relationships and caring for aging parents
  • Tips for creating low-stress, meaningful holidays with aging loved ones
  • The causes of anxiety within families during the holiday season
  • Knowing when a higher level of help is needed as well as the available options

To learn more about Empower Hour and to register for the webcast, visit: www.elmcroft.com/empower.

About Eclipse Senior Living

Eclipse Senior Living is a national manager of distinctive Independent, Assisted Living and Memory Care communities across the United States, including the brands Elmcroft™ and Embark™. The Eclipse Senior Living portfolio includes over 100 communities in more than 25 states. To learn more about Eclipse Senior Living, visit: https://www.eclipseseniorliving.com/.

1 National Alliance for Caregiving and AARP (2015)
2 Gallup-Healthways Well-Being Index (2011)



Contact: 
Jamison Gosselin
[email protected]

Professional Community Management Names Matthew Williams as Branch President

Foothill Ranch, CA, Nov. 16, 2020 (GLOBE NEWSWIRE) — Professional Community Management (PCM), an Associa® company, recently named Matthew Williams, CMCA®, AMS®, PCAM®, as the new branch president. 

With more than 14 years of community management experience, including four years at Associa Colorado, first as vice president and most recently as branch president, Matt has demonstrated an ability to work throughout all levels of the business to establish positive relationships with community leaders, clients, and colleagues. His achievements and ability underscore his approach to helping team members grow and succeed, while taking on new responsibilities and continuing his own development.  As a collaborative team player, Matt brings a balance of communication, relationship, analytical and problem-solving skills to his role as PCM’s new president. 

In addition to his professional experience, Mr. Williams brings with him a commitment to giving back to the industry as a volunteer. He served as a delegate on the Community Associations Institute’s (CAI) Colorado Legislative Action Committee (CLAC), where he also helped educate state legislators, providing invaluable advice when community association issues arose.  

“Matt has been a valued member of the Associa family since joining the team, and his industry knowledge, leadership abilities, resourcefulness, and drive make him ideal for this next challenge,” stated Ann Williams, Associa regional vice president. “Matt has an essential understanding of the importance of developing client relationships built on collaboration and communication, and we are excited to have him leading the PCM branch.” 

Mr. Williams earned his Bachelor of Science degree in Business Administration from the University of Wyoming in Laramie. He also holds the Certified Manager of Community Associations (CMCA®) designation from the Community Association Managers International Certification Board (CAMICB) and the Association Management Specialist (AMS®) and Professional Community Association Manager (PCAM®) designations from the Community Associations Institute (CAI). 

With more than 200 branch offices across North America, Associa delivers unsurpassed management and lifestyle services to nearly five million residents worldwide. Our 10,000+ team members lead the industry with unrivaled education, expertise and trailblazing innovation. For more than 40 years, Associa has provided solutions designed to help communities achieve their vision. To learn more, visit www.associaonline.com.

Stay Connected: 

Like us on Facebook: https://www.facebook.com/associa

Subscribe to the Blog: https://hub.associaonline.com/

Follow us on Twitter: https://twitter.com/associa

Join us on LinkedIn: http://www.linkedin.com/company/associa



Ashley Cantwell
Associa 
214-272-4107
[email protected]

CargoAir Switches to AEI for Two (2) AEI B737-800SF Freighter Conversions

MIAMI, Nov. 16, 2020 (GLOBE NEWSWIRE) — Aeronautical Engineers, Inc. (AEI) today announced the company has signed a contract to provide Bulgaria-based CargoAir with two AEI B737-800SF Freighter Conversions. CargoAir originally signed agreements for two B737-800BCF conversions, however, the company recently cancelled those agreements and signed up with AEI – citing AEI’s responsiveness, slot flexibility, ease of doing business, and the intrinsic value the AEI B737-800SF provides as a better-priced option. This past year AEI added two additional authorized AEI Conversion Centers and currently has slots available starting in May 2021.

“CargoAir is a highly valued customer, which currently operates three AEI B737-300SF and seven AEI B737-400SF freighters. At present, we are converting a B737-400SF for CargoAir, which will be redelivered in January 2021,” stated Robert T. Convey, AEI Senior Vice President Sales & Marketing. “We are proud that CargoAir continues to recognize the extraordinary business value of all our freighter conversion products, including the B737-800SF, and we are delighted that our renowned accommodative business approach and responsive customer service has again been affirmed with this recent order.”

CargoAir’s recently acquired B737-800 aircraft (MSN 30664) is scheduled to commence modification in January 2021. All modification touch labor will be performed by the authorized AEI Conversion Center, Commercial Jet, in Dothan, Alabama.

CargoAir will benefit from AEI’s B737-800SF main deck payload of up to 52,700 lbs. (23,904 kg) and its eleven full height 88” x 125” container positions, plus an additional position for an AEP/AEH. The conversion also incorporates new floor beams aft of the wing box, a large 86” x 137” Main Cargo Door with a single vent door system, and a flexible Ancra Cargo Loading System. The AEI B737-800SF also includes a rigid 9g barrier, five supernumerary seats as standard, a galley and full lavatory.

When combined with proven reliability, ruggedness, and low cost, the AEI Converted B737-800SF will allow CargoAir to keep their aircraft – “In the air, generating revenue”.

A
bout AEI

Aeronautical Engineers, Inc. (AEI) is a global leader in the aircraft passenger-to-freighter conversion business and is the oldest conversion company in existence today. Since the company’s founding in 1958, AEI has developed over 130 Supplemental Type Certificates (STCs) and has modified over 510 aircraft with the STCs. AEI helps its customers extend aircraft life and increase the overall value of aircraft assets by continuously focusing on dependable and flexible product offerings. AEI currently offers passenger-to-freighter conversions for the Boeing 737-800, 737-400, 737-300, MD-80 series, and CRJ200 aircraft. www.aeronautical-engineers.com

About CargoAir

CargoAir is a Sofia, Bulgaria-based cargo airline. The company was founded in 1997, initially operating six AN-12 aircraft. CargoAir currently operates a fleet of three B737-300 and seven B737-400 freighters. CargoAir has established long-term operations for Integrated Express and Mail operators such as DHL and UPS and has contracted its freighter fleet to support their specific network requirements. The company is also dedicated to ad hoc cargo charter flights worldwide, providing customer-oriented solutions for cargo brokers, freighter forwarders and logistics companies requiring the transportation of dangerous goods, special cargo, and outsized loads. www.cargoair.bg.

AEI Contact:

Robert T. Convey
Senior Vice President Sales & Marketing
+1 (818) 406-3666
[email protected]



GitLab Appoints Chief People Officer and Newest Board Member

SAN FRANCISCO, Nov. 16, 2020 (GLOBE NEWSWIRE) — GitLab, the DevOps platform delivered as a single application, announced today the appointment of Wendy Nice Barnes as Chief People Officer (CPO) and Merline Saintil to its board of directors. Both additions bring extensive experience to the company and will help GitLab further its position as a leading DevOps platform.

“As GitLab continues to grow, it is vital to our success to bring onboard key individuals who will help us maintain high growth and market leadership,” said Sid Sijbrandij, co-founder and CEO of GitLab. “Wendy has an impressive history of mentoring colleagues and growing leaders from within organizations. While Merline’s global award-winning product creation has enabled Fortune 500 companies to manage cyber risk at scale. Both embody our CREDIT values and are tremendous additions to the company.”

Barnes joins GitLab with over 20 years of Talent leadership experience in pre-IPO and Fortune 500 companies. She served as Chief Human Resources Officer at Palo Alto Networks, Vice President of Human Resources at eHealth, and held senior HR leadership roles at Netflix and E*TRADE.

“GitLab is not only a shining example of how to run a successful all remote company, but they are consistently recognized as a top company to work for,” said Barnes. “I am looking forward to joining such a transparent group of people, leading with the members of the executive team and working closely with its DIB (Diversity, Inclusion and Belonging) and remote leaders to further the great foundation set forth.”

Saintil currently serves on the boards of Lightspeed, Alkami Technology, Banner Corporation, and ShotSpotter and was recognized as one of the Most Influential Corporate Board Directors by Women Inc. She is a member of the National Association of Corporate Directors (NACD) and is certified in Cybersecurity Oversight by NACD and the Carnegie Mellon Software Engineering Institute. Saintil previously held leadership roles with iconic Fortune 500 and privately held companies including Intuit, Yahoo!, PayPal, Adobe, Joyent and Sun Microsystems. She has also received a Lifetime Achievement Award by Girls in Tech.

“GitLab has enabled its enterprise customers to shift left by seamlessly incorporating security into its single DevOps platform making them a unique company to watch,” said Saintil. “I’m honored to join its board of directors and have the opportunity to bring my engineering, enterprise risk and cybersecurity experience to support the company as it grows its footprint globally.”

GitLab Velocity and Recognition

The company has experienced 50x growth in 4 years and surpassed $150M in annual recurring revenue earlier this year with more than 30M estimated registered users.

GitLab recently ranked 13 on the Forbes’ 2020 Cloud 100 List (up from 32nd place in 2019) and was listed on the Enterprise Tech 30 2020 as a late-stage private company. GitLab also earned the ranking of no. 268 on the 2020 Inc. 5000 list of the fastest-growing private companies in America.


Workplace Recognition

GitLab placed 35th on Forbes’ 2020 list of America’s Best Startups for Employers and made the Inc.’s Best Workplaces of 2020 (for the second year in a row). The company was named a finalist in the Workplace category in Fast Company’s 2020 Innovation by Design Awards, listed as a top employer in Hired’s Brand Health Report, is among Fortune’s 100 Best Small & Medium Workplaces in 2020, and was named “2020 Best Company to Work for” by the Product Marketing Alliance. 2020 Working Mother Media listed GitLab among the 100 Best Companies for successfully helping employees integrate home and work life.


Product Recognition

GitLab 13.0 recently won 2020 CRN Tech Innovator Awards in the IT/Application Automation category. The company was also recognized as a “451 Firestarter” by 451 Research and was awarded the DevOps Dozen award for Best DevOps Solution Provider by industry leaders MediaOps and DevOps.com, Forrester named the company a 2020 Strong Performer for Continuous Delivery and Release Automation and Gartner cited GitLab as a Visionary in its Enterprise Agile Planning Tools Magic Quadrant and named the company a 2020 Customers’ Choice for Application Release Orchestration in its Peer Insights “Voice of the Customer” review.

About GitLab

GitLab is a DevOps platform built from the ground up as a single application for all stages of the DevOps lifecycle enabling Product, Development, QA, Security, and Operations teams to work concurrently on the same project. GitLab provides a single data store, one user interface, and one permission model across the DevOps lifecycle. This allows teams to significantly reduce cycle times through more efficient collaboration and enhanced focus.

Built on Open Source, GitLab works alongside its growing community, which is composed of thousands of developers and millions of users, to continuously deliver new DevOps innovations. More than 100,000 organizations from startups to global enterprises, including Ticketmaster, Jaguar Land Rover, NASDAQ, Dish Network, and Comcast trust GitLab to deliver great software faster. All-remote since 2014, GitLab has more than 1,300 team members in 68 countries.

Media Contact

Natasha Woods

GitLab

[email protected]



Robert Barnhill, Jr. Reminds Shareholders of Their Right to Remove TESSCO Directors Hastily Appointed Last Week Without Shareholder Approval

Submitting a WHITE Consent Card FOR the Removal of Any of John D. Beletic, Jay G. Baitler, Paul J. Gaffney, Morton F. Zifferer, Jr. or Dennis J. Shaughnessy Constitutes a Consent to Remove Cathy-Ann Martine-Dolecki, Ronald D. McCray and Any Other Directors Appointed to the Board Prior to the Conclusion of the Consent Solicitation

Consent to the Election of Robert Barnhill Jr.’s Highly-Qualified Independent Candidates to the TESSCO Board

PR Newswire

HUNT VALLEY, Md., Nov. 16, 2020 /PRNewswire/ — On November 16, 2020, Robert B. Barnhill, Jr., founder and largest shareholder of TESSCO Technologies, Incorporated (NASDAQ: TESS) (“TESSCO” or the “Company”), issued the following press release in response to the dubiously-timed additions to the Company’s Board of Directors (the “Board”):

Last week, the Board took what Mr. Barnhill deems an extraordinarily reactionary and defensive tactic to further entrench the majority influence held by incumbent directors, John D, Beletic, Jay G. Baitler and Paul J. Gaffney over a captive Board. We believe that the recent addition of two new directors to the Board without shareholder approval (“Unilateral Board Appointments”) in the middle of a consent solicitation process is rash and reactionary and a failure of good corporate governance. In our view, a slight Board compositional change effected without shareholder approval is not sufficient to remedy the enormous issues facing the Company. Based on the Company’s annual meeting results from 2019 and 2020, we believe it is clear the Board lacked a mandate from shareholders to undertake this exercise, particularly on the eve of its meetings with proxy advisory firms and institutional shareholders. 

Fortunately, Mr. Barnhill’s definitive consent solicitation statement (the “Solicitation Statement”) and accompanying WHITE consent card contemplated the possibility of the Unilateral Board Appointments.

  • Proposal 1 in the Solicitation Statement and WHITEconsent card provides that a consent for the removal of any of John D. Beletic, Jay G. Baitler, Paul J. Gaffney, Morton F. Zifferer, Jr. or Dennis J. Shaughnessy (collectively, the “Subject Directors”) also constitutes a consent to remove any other person(s) elected, appointed or designated by the Board (or any committee thereof) to fill any vacancy or newly created directorship on or after September 25, 2020 and prior to the conclusion of Mr. Barnhill’s consent solicitation (the “Consent Solicitation”); 
  • Consequently, this means that consenting to remove any director named in Proposal 1 on the WHITE consent card also constitutes a consent to remove the two directors recently added as a result of the Unilateral Board Appointments (Cathy-Ann Martine-Dolecki and Ronald D. McCray); and
  • This also means that consenting to remove any director named in Proposal 1 on the WHITE consent card constitutes a consent to remove any additional non-shareholder approved director elected, appointed or designated by the Board during the remainder of the Consent Solicitation.

As a result, removal of any Subject Director1 by the affirmative consent of holders of a majority of shares of the Company’s common stock (“Common Stock”) as of the October 13, 2020 record date will result in the removal of all directors appointed or designated by the Board on or after September 25, 2020 and prior to the completion of the Consent Solicitation, including Ms. Martine-Dolecki and Mr. McCray. 

We believe the Unilateral Board Appointments to be a direct entrenchment tactic and a blatant attempt to confuse shareholders during the Consent Solicitation. We do not believe that the Subject Directors, who have lost shareholder support, should be able to frustrate the will of the shareholders by unilaterally appointing new directors without shareholder approval during a consent solicitation. However, consistent with shareholders’ best interest, following the Consent Solicitation, Mr. Barnhill plans to recommend to the reconstituted Board that it interview Ms. Martine-Dolecki and Mr. McCray for possible directorships, while also taking shareholder feedback into account.

At your earliest convenience, please consent to remove the Subject Directors (which will also result in the removal of Ms. Martine-Dolecki and Mr. McCray, the two directors recently appointed as a result of the Unilateral Board Appointments), and replace them with our four highly-qualified independent candidates—J. Timothy Bryan, John W. Diercksen, Emily Kellum (Kelly) Boss and Kathleen McLean.

TAKE ACTION TODAY!

Consent and Consent Revocation Procedures

We urge you to consent to all four proposals on the WHITE consent card and return it in your postage-paid envelope provided prior to December 11, 2020. An executed consent card may be revoked at any time by marking, dating, signing and delivering a written revocation before the time that the action authorized by the executed consent becomes effective. A revocation may be in any written form validly signed by the record holder as long as it clearly states that the consent previously given is no longer effective. The delivery of a subsequently dated consent card that is properly completed will constitute a revocation of any earlier consent. The revocation may be delivered to Harkins Kovler, LLC at the address set forth below.
If you hold your share in “street” name with a brokerage firm, bank, dealer, trust company or other nominee, please consult such nominee for instructions on how to consent or revoke your consent.

If you have any questions about the Consent Solicitation or need assistance executing the WHITE consent card, please contact:


Harkins Kovler, LLC

3 Columbus Circle, 15th Floor


New York, NY 10019

Telephone: +1 (212) 468-5380

Toll-Free: +1 (800) 257-3995

Email: [email protected]

Important Additional Information

Mr. Barnhill, Ms. McLean, Ms. Boss, Mr. Bryan, Mr. Diercksen, UA 6-9-2016Robert B. Barnhill, Jr. Rev Trust, RBB-TRB LLC, a Maryland limited liability company (“RBB-TRB”), RBB-CRB LLC, a Maryland limited liability company (“RBB-CRB”), Robert B Barnhill Jr & Janet W Barnhill Tr FBO Durkin Slattery Barnhill Trust, Janet W Barnhill Tr UA 6 9 2016 Janet W Barnhill Rev Trust, Winston Foundation, Incorporated, a Maryland corporation, and Donald Manley (the “Participants” or “We”) are participants in the solicitation of consents from the Company’s shareholders to remove the Subject Directors (and any other person or persons, other than those elected by the Consent Solicitation, elected, appointed or designated by the Board (or any committee thereof) to fill any vacancy or newly created directorship on or after September 25, 2020 and prior to the time that any of the actions proposed to be taken by the Consent Solicitation become effective) and elect Ms. McLean, Ms. Boss, Mr. Bryan and Mr. Diercksen to fill four of the resulting vacancies (as well as to amend the Company’s Sixth Amended and Restated By-Laws proposed in connection therewith). We have filed the Solicitation Statement and a WHITE consent card with the Securities and Exchange Commission (the “SEC”) in connection with any such solicitation of proxies from the Company’s shareholders.

SHAREHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ THE SOLICITATION STATEMENT, ACCOMPANYING WHITE CONSENT CARD AND ALL OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY AS THEY CONTAIN IMPORTANT INFORMATION. UPDATED INFORMATION REGARDING THE IDENTITY OF POTENTIAL PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE, IS SET FORTH IN THE SOLICITATION STATEMENT AND OTHER MATERIALS FILED WITH THE SEC. Shareholders can obtain the Solicitation Statement and any amendments or supplements to the Solicitation Statement filed by the Participants with the SEC at no charge at the SEC’s website at www.sec.gov. Copies will also be available, without charge, on request from the Participants’ proxy solicitor, Harkins Kovler, LLC at +1 (800) 257-3995 or via email at [email protected].

Certain Information Regarding the Participants

Mr. Barnhill is the founder, former Chairman of the Board and the largest shareholder of the Company.

Mr. Barnhill beneficially owns 1,620,387 shares of the Common Stock (approximately 18.5% of the outstanding shares), which includes 11,503.5 shares that Mr. Barnhill owns directly and the shares owned by the following Participants: UA 6-9-2016Robert B. Barnhill, Jr. Rev Trust owns 1,265,882 shares of Common Stock, RBB-TRB, LLC owns 109,125 shares of Common Stock, RBB-CRB, LLC owns 109,125 shares of Common Stock, Robert B Barnhill Jr & Janet W Barnhill Tr FBO Durkin Slattery Barnhill Trust, owns 30,750 shares of Common Stock, Janet W Barnhill Tr UA 6 9 2016 Janet W Barnhill Rev Trust owns 67,500 shares of Common Stock, and the Winston Foundation, Incorporated owns 26,500 shares of Common Stock. Mr. Barnhill is the sole manager of RBB-TRB and RBB-CRB, a trustee of the UA 6-9-2016Robert B. Barnhill, Jr. Rev Trust and the Robert B Barnhill Jr & Janet W Barnhill Tr FBO Durkin Slattery Barnhill Trust and a director of the Winston Foundation, Incorporated. Mr. Barnhill’s spouse is a trustee of the Janet W Barnhill Tr UA 6 9 2016 Janet W Barnhill Rev Trust. The percentage of Mr. Barnhill’s stock ownership is based on the 8,760,562 shares of Common Stock outstanding as of October 13, 2020, as reported in the Company’s Consent Revocation Statement on Schedule 14A, filed with the SEC on October 15, 2020. Christopher Barnhill may be considered a Participant in the solicitation but is no longer providing any assistance with respect to the solicitation and does not currently beneficially, directly or indirectly own any securities of the Company.

None of the Participants (other than Mr. Barnhill) currently beneficially, directly or indirectly own any securities of the Company.

Investor/Media Contacts:

Harkins Kovler, LLC
Peter Harkins, Jr. / Rahsaan Wareham
(212) 468-5394 / (212) 468-5399
[email protected] / [email protected]


1 Mr. Shaughnessy was originally a Subject Director targeted for removal by the Consent Solicitation. However, he retired in connection with the Unilateral Board Appointments. Therefore, shareholder approval of the removal of Mr. Shaughnessy will only have the effect of removing all directors appointed or designated by the Board on or after September 25, 2020 and prior to the completion of the Consent Solicitation.

 

Cision View original content:http://www.prnewswire.com/news-releases/robert-barnhill-jr-reminds-shareholders-of-their-right-to-remove-tessco-directors-hastily-appointed-last-week-without-shareholder-approval-301173916.html

SOURCE Mr. Robert B. Barnhill, Jr.

SINTX Technologies Shares Q3 Business Update and Identifies Growth Opportunities for 2021

SALT LAKE CITY, Nov. 16, 2020 (GLOBE NEWSWIRE) — SINTX Technologies, Inc. (www.sintx.com) (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer of silicon nitride ceramic for medical and non-medical applications, shared details on its Q3 business update and new business opportunities ahead.

Throughout the pandemic, SINTX has continued to address the impact of COVID-19 on its business operations. The Company has avoided layoffs and invested in the safety of its employees through new protocols and work from home policies. As such, SINTX has been able to maintain business operations as usual in Q3, except for the reduction in spine sales which we discuss below.

“Despite an unpredictable year, we feel fortunate that our business has been able to minimize the impact of COVID-19,” said Dr. Sonny Bal, President, and CEO, SINTX Technologies. “Our business has been able to hire new employees, expand necessary research and development, and engage with new customers to create a variety of applications using our silicon nitride. As one example, we manufactured and shipped industrial prototype parts for the first time in our history. We’re looking forward to additional growth in 2021 and aggressively pursuing the opportunities in front of us.”

Third Quarter Financial Results

SINTX reported revenue of $0.1 million for the three months ended September 30, 2020, and $0.5 million for the nine months ended September 30, 2020. Generally accepted accounting principles (GAAP) basic net loss for the three months ended September 30, 2020, was $0.11 per share, compared to a basic net loss of $0.68 per share for the three months ended September 30, 2019. For the nine months ended September 30, 2020, the Company reported a GAAP basic net loss of $0.39 per share, compared to a basic net loss of $3.00 per share for the nine months ended September 30, 2019. The Company’s cash and cash equivalents were $27.1 million as of September 30, 2020, an increase of $25.3 million from December 31, 2019.

The Company shipped one aerospace prototype order in the quarter. The balance of the revenue came from sales of production and prototype components to CTL Amedica.

SINTX reported a significant reduction in the number of remaining unconverted preferred shares from the May 2018 and February 2020 offerings as well as in the number of unexchanged warrants. The details can be found in the 10-Q.

Medical Devices Update

Overall, revenue from medical devices was predictably down due to hospital restrictions on elective surgeries taking place during the COVID-19 pandemic. Those restrictions are expected to continue to hurt US sales to CTL Amedica of the Valeo product line. However, CTL Amedica has gained regulatory clearance in Taiwan and future sales to CTL Amedica are anticipated in support of the expected growth from that new opportunity. Furthermore, SINTX and CTL Amedica have been collaborating on the development of new spinal implants made from monolithic silicon nitride and SINTX’s Silicon Nitride-PEEK composite, and sales from those products are expected in 2021.

The COVID-19 pandemic has also impacted SINTX’s collaborative efforts in the dental market. However, SINTX’s partners have recently renewed contact and those projects are moving forward. These projects are looking both at monolithic silicon nitride implants as well as coatings of silicon nitride on titanium implants. Revenue from these opportunities is not expected for several years as silicon nitride is a novel material in dental applications, and would have a lengthy regulatory pathway to navigate.

SINTX has previously referenced a Material Transfer Agreement with a global medical device manufacturer and this project is also still active. Progress has been impacted by the COVID-19 pandemic as well as by the Company’s emphasis on research and development of novel antipathogenic applications for the Company’s silicon nitride.

SINTX added a new U.S. Patent for antibacterial applications of silicon nitride to its technology IP portfolio in Q3. The issued US Patent 10,806,831 broadly covers a variety of biomedical implants wherein the Company’s silicon nitride is applied to improve the antibacterial characteristics of the implant. The first composite product protected under this patent has already been developed and is expected to be commercialized in 2021.

The Company believes there are significant future revenue-generating opportunities in the medical device market. In support of that belief, Michael Marcroft was recently hired as a Vice President of Business Development to identify and grow new opportunities in this market. Silicon nitride’s twelve years of successful outcomes in spinal fusion surgery provide a solid foundation for new medical device applications.

Non-Medical Product Opportunities Ahead

SINTX has experienced growth of customer interest in antipathogenic silicon nitride applications. The Company is in active product development discussions with automotive, IT device, face mask, and air filter manufacturers. SINTX’s partnership with O2TODAY to develop a “catch-and-kill” mask that will inactivate respiratory viruses and bacteria continues to progress and is in the manufacturing process development stage. SINTX continues to prioritize the product development of antipathogenic applications through workforce expansion, acquisition of prototype manufacturing and supporting laboratory equipment, and the development of test protocols to assess the antipathogenic properties of new products.

SINTX has gained the ability to enter the aerospace and defense markets through its recently announced AS9100D certification, which enables SINTX to supply components directly to these industries. The certification means that SINTX now meets the highly stringent standards of these industries and is listed in the OASIS database, used by aerospace suppliers like Boeing, Lockheed Martin, Raytheon, United Technologies, North Grumman, and the United States military. The Company has received orders for and shipped prototype components to companies in this industry.

With new partnership opportunities in place and a shift in business focus toward antipathogenic applications, SINTX has decided not to pursue its previously-announced relationship with Nissin.

Research & Development Updates

In prior years, SINTX made a substantial investment to confirm and understand the osteogenic and antipathogenic properties of the Company’s silicon nitride. The Company has now pivoted towards an R&D investment strategy that is focused on developing products for new markets that leverage these properties.

Where appropriate, SINTX has sought additional funding through highly-competitive external grant opportunities. Although no awards have been received to-date, SINTX’s solid financial condition means that this has not impacted the pace of its research and development activities.

“Our focus going into 2021 is to develop and commercialize silicon nitride-embedded fabrics for a variety of applications,” said Dr. Bal. “Another focus is the commercialization of our polymer-silicon nitride composite technology. The third area of focus is the development of silicon nitride coatings on titanium. All of these areas of focus target multiple opportunities in the medical as well as the non-medical markets. In addition, we are aggressively targeting the industrial markets for silicon nitride, including selected strategic opportunities in that space. We are well-capitalized to make the necessary investments in personnel and equipment to generate new revenues.”

About SINTX Technologies, Inc.

SINTX Technologies is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The core strength of SINTX Technologies is the manufacturing, research, and development of silicon nitride ceramics for external partners. The Company presently manufactures silicon nitride powders and components in its FDA registered, ISO 9001:2015 certified, ISO 13485:2016 certified, and AS9100D certified manufacturing facility.

For more information on SINTX Technologies or its silicon nitride material platform, please visit www.sintx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) that are subject to a number of risks and uncertainties. Risks and uncertainties that may cause such differences include, among other things: incorporation of silicon nitride into personal protective equipment may not be safe or effective; volatility in the price of SINTX’s common stock; the uncertainties inherent in new product development, including the cost and time required to commercialize such product(s); market acceptance of our products once commercialized; SINTX’s ability to raise additional funding and other competitive developments. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 26, 2020, and in SINTX’s other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.

Business Inquiries for SINTX:

SINTX Technologies
801.839.3502
[email protected]

Media Inquiries for SINTX:

Amanda Barry
Associate Director, Content and PR
The Summit Group
[email protected]



HD SUPPLY ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of HDS and Encourages Investors to Contact the Firm

NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of HD Supply Holdings, Inc. (NASDAQ: HDS) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by The Home Depot, Inc. (NYSE: HD).

Click here to learn more and participate in the action.

On November 16, 2020, HD Supply announced that it had signed an agreement to be acquired by Home Depot for approximately $8 billion. Pursuant to the merger agreement, HD Supply stockholders will receive $56 in cash for each share of HD Supply common stock owned. The deal is scheduled to close in the first quarter of 2021.

Bragar Eagel & Squire is concerned that HD Supply’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for HD Supply’s stockholders.

If you own shares of HD Supply and are concerned about the proposed merger, or you are interested in learning more about the investigation or your legal rights and remedies, please contact Melissa Fortunato or Alexandra Raymond by email at [email protected] or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Bragar Eagel & Squire, P.C.
Melissa Fortunato, Esq.
Alexandra Raymond, Esq.
[email protected]
www.bespc.com



Tauriga Sciences Inc. Extends its Relationship with Alibaba Group for a Period of an Additional 12 Months

NEW YORK, NY, Nov. 16, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnology initiatives, today announced that it has extended its relationship with Chinese E-Commerce & Retail giant, Alibaba Group (“Alibaba”), for a period of an additional 12 months.  The Company’s status as an Alibaba “Gold Supplier Member” has been extended until the following date:  December 31, 2021.  The Company has established many important relationships and expanded its international Tauri-Gum™ brand presence, through this relationship with Alibaba. 

Over the course of the next few months, the Company plans to establish an E-Commerce page, through the Alibaba commercial platform, constructed in Mandarin Chinese (“Mandarin”).  To further enhance its ability to sell Tauri-Gum™ throughout China, the Company will provide a Tauri-Gum™ blister pack design version – in Mandarin.   

ABOUT TAURIGA SCIENCES INC.

Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives.  The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment.  The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant) & (Vitamin C + Zinc “Immune Booster” Tauri-Gum™ Flavor: Pear Bellini).  The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com

Complementary to the Company’s retail business, are its two ongoing biotechnology initiatives.  The first one relates to the development of a Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed to help patients that are subjected to ongoing chemotherapy treatment). On March 18, 2020, the Company announced that it filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™.  The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. The second one relates to a collaboration agreement with Aegea Biotechnologies Inc. for the co-development of a rapid, multiplexed, Novel Coronavirus (COVID-19) test with superior sensitivity and selectivity.   

On October 6, 2020, the Company announced that it has been approved to operate as a U.S. Government Vendor (CAGE CODE # 8QXV4)

On October 7, 2020 the Company disclosed a Strategic Alliance with Think BIG, LLC, Social Impact Startup Founded by CJ Wallace, Son of Christopher “The Notorious B.I.G.” Wallace.

The Company is headquartered in New York City and operates a regional office in Barcelona, Spain.  In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New York.

DISCLAIMER — Forward-Looking Statements

This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in  forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.

Contact:

Tauriga Sciences, Inc.
555 Madison Avenue, 5th Floor
New York, NY  10022
Chief Executive Officer
Mr. Seth M. Shaw
Email:  [email protected]
cell # (917) 796 9926
Instagram: @taurigum
Twitter: @SethMShaw
Corp. Website:   www.tauriga.com
E-Commerce Website:  www.taurigum.com



Pressure BioSciences, Inc. to Discuss Third Quarter 2020 Financial Results and Provide Business Update

Conference Call Scheduled for Tuesday, November 17th at 4:30pm ET

PR Newswire

SOUTH EASTON, Mass., Nov. 16, 2020 /PRNewswire/ — Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”) today announced that the Company will host a teleconference to discuss its Third Quarter 2020 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a link on the Company’s website) approximately one day after the teleconference.

The teleconference will include a Company presentation followed by a Question & Answer period.

Date:  Tuesday, November 17, 2020.  
Time:  4:30 PM Eastern Time (ET).

To attend this teleconference, live by telephone: Dial-in: (877) 407-8033 (North America); (201) 689-8033 (International). Verbal Passcode: PBI Third Quarter 2020 Financial Call & Business Update.

For those unable to participate in the live teleconference, a replay will be available beginning Wednesday, November 18, 2020.  The replay will be accessible via telephone and the Company’s website for 30 days.

Replay Number: (877) 481-4010 (North America); (919) 882-2331 (Int’l); Replay Passcode: 38901.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

For more information about PBI and this press release, please click on the following link: http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter. 

Investor Contacts

Richard T. Schumacher, President & CEO, (T) 508-230-1828, Jeffrey N. Peterson, Chairman of the Board, (F) 508-230-1829

 

 

Cision View original content:http://www.prnewswire.com/news-releases/pressure-biosciences-inc-to-discuss-third-quarter-2020-financial-results-and-provide-business-update-301173928.html

SOURCE Pressure BioSciences, Inc.